US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Pfizer Inc.

PFENYSE

52.47

USD
+1.82
(+3.59%)
Market Closed
12.03P/E
1Forward P/E
0.46P/E to S&P500
294.404BMarket CAP
3.10%Div Yield

Pfizer Inc.

NYSE:PFE

RECENT
PRICE

52.47

P/E
RATIO

12.03

(PEG:0.10)

P/E RATIO
RELATIVE
TO S&P

0.46

DIV
YLD

3.21%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

0.71 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 05/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

6.68

2.67

2.15

0.96

7.00

1.18

1.66

1.15

7.18

1.20

2.46

1.27

7.14

1.23

2.20

0.79

8.44

1.03

1.24

0.76

8.63

1.28

2.38

0.80

7.93

1.96

2.11

0.88

7.57

3.23

2.39

0.97

7.82

1.44

2.41

1.04

7.91

1.13

2.11

1.12

8.68

1.18

2.28

1.20

8.80

3.57

2.39

1.28

9.14

1.90

2.32

1.36

9.29

2.92

1.79

1.44

7.54

1.73

2.09

1.52

14.51

3.92

5.39

1.56

16.47

4.44

5.67

1.57

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.28

9.85

0.27

9.40

0.25

8.56

0.17

12.85

0.19

10.93

0.21

10.51

0.18

10.92

0.22

11.20

0.25

11.24

0.24

10.48

0.33

9.78

0.37

11.94

0.37

10.80

0.47

11.34

0.50

11.38

0.48

13.83

0.50

13.61

CAPEX per share

Book Value per share

7,242

6,917

6,727

7,007

8,036

7,817

7,442

6,813

6,346

6,176

6,089

5,970

5,872

5,569

5,555

5,601

5,610

Comm.Shares outs.(m)

9.1

0.5

3.9%

20.3

1.2

4.8%

15.2

0.7

6.9%

12.0

0.2

5.3%

15.5

0.7

4.8%

14.4

0.9

4.3%

11.2

0.8

4.0%

8.5

0.5

3.5%

20.0

1.1

3.6%

28.2

1.4

3.5%

26.2

1.2

3.9%

9.0

0.4

4.0%

19.6

0.8

3.7%

12.9

0.5

3.8%

20.2

0.5

4.3%

10.7

0.4

3.7%

12.0

0.5

3.2%

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (3/4/22 | Q1)

Total liabilities
$101,155 m.

Total assets
$183,841 m.

Long-term debt
$35,656 m.

Cash and equiv.
$2,470 m.

Goodwill $50,211 m.

Retained earnings $111,193 m.

Common stock 5,616 m. shares

Market Capitalisation
$294,404 m. (as of 21/5/22)

67,425

27.0%

58,986

30.5%

51,584

31.7%

49,605

27.2%

48,851

26.6%

52,824

26.0%

52,546

26.8%

53,647

28.0%

51,750

26.9%

41,908

20.9%

81,288

24.9%

92,367

25.4%

Revenue (m)

Operating margin

9,026

10,009

7,611

14,570

6,410

22,003

5,537

9,135

5,157

6,960

5,757

7,215

6,269

21,308

6,384

11,153

6,010

16,273

4,777

9,616

5,191

21,979

5,152

24,966

Depreciation (m)

Net profit (m)

31.5%

14.8%

21.2%

24.7%

27.4%

42.7%

25.5%

18.4%

22.2%

14.2%

13.4%

13.7%

(73.5)%

40.6%

5.9%

20.8%

7.8%

31.4%

6.4%

22.9%

7.6%

27.0%

8.1%

27.0%

Income tax rate

Net profit margin

29,659

34,931

82,190

32,796

31,036

81,260

32,878

30,462

76,307

36,071

31,541

71,301

14,405

28,818

64,720

7,834

31,398

59,544

10,714

32,666

71,308

18,068

32,429

63,407

(4,501)

35,955

63,143

9,147

35,571

63,238

17,022

36,195

77,462

15,152

35,656

82,424

Working capital (m)

Long-term debt (m)

Equity (m)

6.7%

8.4%

12.2%

9.4%

10.1%

17.9%

13.6%

16.1%

28.8%

6.9%

8.1%

12.8%

5.7%

6.1%

10.8%

5.9%

5.6%

12.1%

16.6%

7.9%

29.9%

9.7%

8.3%

17.6%

13.6%

11.5%

25.8%

8.4%

7.5%

15.2%

16.7%

13.8%

28.4%

17.9%

15.3%

30.3%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

9,830

10,309

10,469

Receivables

12,068

11,194

11,479

Inventory

8,283

8,046

9,059

Other

2,622

3,606

8,086

Current assets

32,803

35,067

59,693

Acc. Payable

4,220

4,309

5,578

Debt due

16,190

2,703

2,241

Other

16,894

18,908

34,852

Current liab.

37,304

25,920

42,671

37.7%

82.0%

55.2%

93.9%

70.1%

140.3%

27.7%

75.9%

0.3%

100.6%

(1.4)%

88.6%

64.1%

88.8%

28.5%

148.0%

50.6%

169.2%

12.2%

72.7%

60.3%

28.9%

64.7%

34.0%

Plowback ratio

Div.&Repurch. to FCF

Pfizer Inc. (US) started trading on January 1, 1944 (cik: 0000078003), operates in the Healthcare sector (Drug Manufacturers—General industry), has 79,000 full-time employees, and is led by Dr. Albert Bourla. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

18.38%

7.02%

Cash flow

36.33%

15.25%

Earnings

21.48%

28.18%

Dividends

3.33%

3.29%

Book value

2.79%

0.11%

Insider trading

Type

Shares

Date

Damico Jennifer B.

Award

26

05/16/22

Damico Jennifer B.

Sale

4,000

05/16/22

Bourla Albert

Award

10

05/13/22

Johnson Rady A

Award

3

05/13/22

Sahni Payal

Sale

1,408

05/13/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

12,028

11,801

12,131

5,947

41,907

2021

14,582

18,977

24,094

23,635

81,288

2022

25,661

- -

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

0.61

0.62

0.39

0.11

1.73

2021

0.87

0.99

1.45

0.61

3.92

2022

1.40

- -

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

0.38

0.38

0.38

0.38

1.52

2021

0.39

0.39

0.39

0.39

1.56

2022

0.40

- -

- -

- -

- -

05/19/2022

CDC Recommends Covid-19 Boosters for 5- to 11-Year-Olds

The Wall Street Journal - Read more...

05/17/2022

Pfizer’s Covid-19 Booster Cleared for 5- to 11-Year-Olds

The Wall Street Journal - Read more...

05/10/2022

Pfizer to Buy Rest of Biohaven for $11.6 Billion

The Wall Street Journal - Read more...

05/03/2022

Pfizer Sales Soar on Covid-19 Vaccine Sales

The Wall Street Journal - Read more...

04/29/2022

Pfizer’s Covid Pill Failed Study Testing Its Preventive Use

The Wall Street Journal - Read more...

04/07/2022

Pfizer to Buy ReViral for Up to $525 Million

The Wall Street Journal - Read more...

03/29/2022

FDA, CDC Endorse Second Covid-19 Booster Shot for Adults 50 and Over

The Wall Street Journal - Read more...

03/22/2022

Pfizer, Unicef Strike Covid-19 Pill Deal

The Wall Street Journal - Read more...

03/14/2022

Merck’s Covid-19 Pill Heavily Used So Far Despite Concerns

The Wall Street Journal - Read more...

03/01/2022

Pfizer’s Covid-19 Vaccine Protected Kids During Omicron Wave, CDC Study Finds

The Wall Street Journal - Read more...

02/19/2022

FDA Eyes Second Covid-19 Booster Shot

The Wall Street Journal - Read more...

02/18/2022

Lower Omicron Efficacy Led to FDA Delay on Pfizer Shot in Young Kids

The Wall Street Journal - Read more...

02/11/2022

FDA to Take More Time Reviewing Pfizer’s Covid-19 Vaccine in Young Children

The Wall Street Journal - Read more...

02/08/2022

Pfizer Forecasts $54 Billion in 2022 Sales From Covid Vaccine, Treatment

The Wall Street Journal - Read more...

02/08/2022

Peloton, Pfizer, Meta, General Motors: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

01/19/2022

SoFi, Bakkt, Bank of America, Cisco: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

01/18/2022

Pfizer’s New Covid-19 Pill Works Against Omicron in Lab

The Wall Street Journal - Read more...

01/06/2022

CDC Recommends First Covid-19 Boosters for 12- to 15-Year-Olds

The Wall Street Journal - Read more...

01/04/2022

Apple, Ford, Jowell, Carnival: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

01/03/2022

FDA Authorizes Pfizer-BioNTech Booster for 12- to 15-Year-Olds

The Wall Street Journal - Read more...

12/29/2021

Drugmakers Battle Over Patents for Covid-19 Vaccines

The Wall Street Journal - Read more...

12/22/2021

Pfizer’s Covid-19 Pill Is Authorized in U.S.

The Wall Street Journal - Read more...

12/20/2021

Pandemic Trades Roar Back: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

12/17/2021

Pfizer Delays Plans to Seek Authorization of Covid-19 Vaccine for Young Children

The Wall Street Journal - Read more...

12/17/2021

Pfizer Seeks Approval of Covid-19 Shot for 12-to 15-Year-Olds

The Wall Street Journal - Read more...

12/15/2021

Roblox, BlackBerry, Pfizer, Adagio Therapeutics: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

12/14/2021

Pfizer Says Its Pill Likely Works Against Omicron

The Wall Street Journal - Read more...

12/14/2021

Study Finds Two Pfizer Vaccine Doses Offer Less Protection Against Omicron Than Against Delta

The Wall Street Journal - Read more...

12/13/2021

Pfizer to Acquire Arena Pharmaceuticals in $6.7 Billion Deal

The Wall Street Journal - Read more...

12/13/2021

Arena, Harley-Davidson, Bluebird Bio, Peloton: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

12/09/2021

Pfizer-BioNTech Covid-19 Booster Authorized for 16- and 17-Year-Olds

The Wall Street Journal - Read more...

12/08/2021

GameStop, Pfizer, Stitch Fix, SentinelOne: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

12/03/2021

FDA Aims for Speedy Review of Omicron Vaccines and Drugs

The Wall Street Journal - Read more...

12/01/2021

Salesforce, Snowflake, Zscaler, Box: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/30/2021

Omicron Variant Sends Policy Makers Scrambling as Science Lags Behind

The Wall Street Journal - Read more...

11/30/2021

Peloton, Moderna, Marriott, Pfizer: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/30/2021

Pfizer Vaccine Executive Moves to Rival GlaxoSmithKline

The Wall Street Journal - Read more...

11/29/2021

Omicron Variant Has Covid-19 Vaccine Makers Preparing for Worst Case

The Wall Street Journal - Read more...

11/29/2021

Moderna, Coinbase, Occidental, Royal Caribbean: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/26/2021

Zoom Video, Carnival, Peloton, Moderna: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/22/2021

Astra Space, Vonage, Rivian, Zoom Video: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/19/2021

Pfizer-BioNTech, Moderna Covid-19 Boosters for All Adults Backed by FDA, CDC

The Wall Street Journal - Read more...

11/18/2021

U.S. Buys 10 Million Treatment Courses of Pfizer’s Covid-19 Pill

The Wall Street Journal - Read more...

11/17/2021

Biden Administration to Work With Drugmakers to Boost Covid-19 Vaccine Supply

The Wall Street Journal - Read more...

11/17/2021

Lucid, Tesla, Nvidia, Cisco: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/16/2021

Pfizer Submits Covid-19 Pill for FDA Authorization

The Wall Street Journal - Read more...

11/09/2021

Pfizer, BioNTech Ask FDA to Expand Covid-19 Booster Use to All Adults

The Wall Street Journal - Read more...

11/05/2021

Pfizer Says Covid-19 Pill Is 89% Effective in Study

The Wall Street Journal - Read more...

11/05/2021

Peloton, Nvidia, Airbnb, Expedia: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/03/2021

Vaccine Boosters’ Mix-and-Match Efficacy

The Wall Street Journal - Read more...

11/03/2021

Pfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double

The Wall Street Journal - Read more...

11/03/2021

CDC Recommends Pfizer-BioNTech Covid-19 Vaccine in Young Children

The Wall Street Journal - Read more...

11/02/2021

Tesla, Pfizer, Lyft: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

10/29/2021

FDA Authorizes Pfizer Vaccine for Young Children

The Wall Street Journal - Read more...

10/26/2021

Pfizer-BioNTech Covid-19 Vaccine for Young Kids Backed by FDA Advisers

The Wall Street Journal - Read more...

10/23/2021

Pfizer-BioNTech Covid-19 Vaccine for Young Kids Satisfied FDA Criteria, Agency Says

The Wall Street Journal - Read more...

10/22/2021

Moderna and J&J Covid-19 Booster Shots Backed by CDC

The Wall Street Journal - Read more...

10/20/2021

FDA Authorizes Covid-19 Vaccine Boosters From Moderna, J&J

The Wall Street Journal - Read more...

10/18/2021

FDA Nears Approval for Mixing Covid-19 Booster Shots

The Wall Street Journal - Read more...